Trelegy (fluticasone furoate umeclidinium bromide vilanterol trifenatate): Reviews and patient testimonials


Medication indications


Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist (for effects on symptom control see section 5.1).

Molecule: fluticasone furoate, umeclidinium bromide, vilanterol trifenatate

Patients' opinions on Trelegy

In brief

General satisfaction level: 8.00/10 Learn more

Treatment's effectiveness: 8.50/10 Learn more

Ease of use: 9.00/10 Learn more

Adherence to prescription: 9.50/10 Learn more

Detected side effects: 2.00/10 Learn more

Improvement in the quality of life: 7.50/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

on 07/07/2020

Seems to be a combination of two other inhalers, relvar and incruse,  which I had been using for a couple of years. Touch wood, I haven’t had a COPD flare-up for eight months, which is good, although my shortage pf breath hasn’t improved.

Your message

on 05/05/2020

Easy to use, seems more effective than previous medication, no side effects

Your message

on 20/02/2019

Easier to use than some other inhalers, seems effective with no noticeable side effects. 

Your message

Members using this Trelegy

Conditions related to this medication

Fact sheet


See the fact sheet